Serum albumin and FT3/FT4 ratio as additional co-morbidity parameters to predict mortality as a new approach: The Haseki Scoring Index (updated Charlson Comorbidity Index).
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
30
06
2021
accepted:
15
02
2022
entrez:
14
3
2022
pubmed:
15
3
2022
medline:
27
4
2022
Statut:
epublish
Résumé
Charlson Comorbidity Index (CCI) is the common and valid method to predict mortality by classifying comorbidities such as cardiovascular, metabolic, renal, hepatic, pulmonary diseases, and malignancy. Novel risk factors are not included in the Charlson Comorbidity Index, such as thyroid hormone index (FT3/FT4 ratio) and serum albumin levels. In the present study, we aimed to assess whether the thyroid hormone index and albumin are useful clinical parameters in short and long-term mortality. In the retrospective cohort study with a 5 year follow up, the data of 1292 patients who were hospitalized between January 1st-June 30th of 2014 were examined. Three months mortality as short term and 5-year mortality as long term were evaluated. Three months and 5 years mortality rates for 1064 patients were analyzed. We showed that hypoalbuminemia and thyroid hormone index had statistically significant effects on short and long-term mortality. According to ROC analysis it was demonstrated that the scoring system including biochemical parameters such as thyroid hormone index and serum albumin level was more significant for 3-month mortality. In addition, both scoring systems are equal in demonstrating long-term mortality. Thyroid hormone index and albumin could improve the prognostic performance of the original Charlson Comorbidity Index in short term mortality. The combined score may offer improvements in comorbidity summarization over existing scores.
Sections du résumé
BACKGROUND
Charlson Comorbidity Index (CCI) is the common and valid method to predict mortality by classifying comorbidities such as cardiovascular, metabolic, renal, hepatic, pulmonary diseases, and malignancy. Novel risk factors are not included in the Charlson Comorbidity Index, such as thyroid hormone index (FT3/FT4 ratio) and serum albumin levels. In the present study, we aimed to assess whether the thyroid hormone index and albumin are useful clinical parameters in short and long-term mortality.
METHODS
In the retrospective cohort study with a 5 year follow up, the data of 1292 patients who were hospitalized between January 1st-June 30th of 2014 were examined. Three months mortality as short term and 5-year mortality as long term were evaluated.
RESULTS
Three months and 5 years mortality rates for 1064 patients were analyzed. We showed that hypoalbuminemia and thyroid hormone index had statistically significant effects on short and long-term mortality. According to ROC analysis it was demonstrated that the scoring system including biochemical parameters such as thyroid hormone index and serum albumin level was more significant for 3-month mortality. In addition, both scoring systems are equal in demonstrating long-term mortality.
CONCLUSION
Thyroid hormone index and albumin could improve the prognostic performance of the original Charlson Comorbidity Index in short term mortality. The combined score may offer improvements in comorbidity summarization over existing scores.
Identifiants
pubmed: 35286325
doi: 10.1371/journal.pone.0264724
pii: PONE-D-21-21373
pmc: PMC8920220
doi:
Substances chimiques
Serum Albumin
0
Thyroid Hormones
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0264724Déclaration de conflit d'intérêts
he authors have declared that no competing interests exist.
Références
J Crit Care. 2019 Jun;51:139-144
pubmed: 30825787
Int J Clin Pract. 2019 Jun;73(6):e13314
pubmed: 30664804
PLoS One. 2014 Aug 22;9(8):e105983
pubmed: 25148079
Circulation. 2002 Dec 3;106(23):2919-24
pubmed: 12460872
JAMA. 1998 May 13;279(18):1477-82
pubmed: 9600484
J Clin Endocrinol Metab. 2012 Nov;97(11):3944-50
pubmed: 22879629
J Am Geriatr Soc. 2016 Mar;64(3):553-60
pubmed: 27000328
J Clin Invest. 2005 Sep;115(9):2524-33
pubmed: 16127464
Eur J Intern Med. 2018 Nov;57:91-95
pubmed: 30029851
J Clin Endocrinol Metab. 2016 Nov;101(11):4385-4394
pubmed: 27552542
J Clin Endocrinol Metab. 1983 May;56(5):883-8
pubmed: 6403568
J Endocrinol. 2015 Jun;225(3):R67-81
pubmed: 25972358
Rev Med Liege. 2014 May-Jun;69(5-6):315-7
pubmed: 25065238
Injury. 2017 Feb;48(2):436-440
pubmed: 28040258
Maturitas. 2015 May;81(1):17-27
pubmed: 25782627
Am J Kidney Dis. 2006 Jan;47(1):139-48
pubmed: 16377395
J Clin Endocrinol Metab. 2005 Dec;90(12):6403-9
pubmed: 16174720
Am J Epidemiol. 2011 Mar 15;173(6):676-82
pubmed: 21330339
J Clin Gastroenterol. 2006 Aug;40(7):592-5
pubmed: 16917399
Neurol Sci. 2016 Sep;37(9):1443-8
pubmed: 27166707
Biomarkers. 2019 Nov;24(7):631-637
pubmed: 31379211
Semin Dial. 2004 Nov-Dec;17(6):432-7
pubmed: 15660573
Sci Rep. 2018 Oct 8;8(1):14977
pubmed: 30297724
Aging Clin Exp Res. 2018 Aug;30(8):927-933
pubmed: 29124524
Aging (Albany NY). 2017 Oct 25;9(10):2223-2234
pubmed: 29070732
J Gastrointest Surg. 2004 Dec;8(8):1041-8
pubmed: 15585392
Am J Cardiol. 2017 Apr 1;119(7):951-958
pubmed: 28160977